Erman Akkus: KRAS mutations in pancreatic cancer
Erman Akkus, Medical Oncology fellow at Ankara University, Faculty of Medicine, shared a recent article by Anna M. Varghese and colleagues on X:
“KRAS mutations in pancreatic cancer in Nature Medicine.
95% of pancreatic cancers are KRAS mutants.
KRAS mut-allele dosage, OS.
Targeting KRAS.”
Authors: Anna M. Varghese, Maria A. Perry, Joanne F. Chou, Subhiksha Nandakumar, Daniel Muldoon, Amanda Erakky, Amanda Zucker, Christopher Fong, Miika Mehine, Bastien Nguyen, Olca Basturk, Fiyinfolu Balogun, David P. Kelsen, A. Rose Brannon, Diana Mandelker, Efsevia Vakiani, Wungki Park, Kenneth H. Yu, Zsofia K. Stadler, Mark A. Schattner, William R. Jarnagin, Alice C. Wei, Debyani Chakravarty, Marinela Capanu, Nikolaus Schultz, Michael F. Berger, Christine A. Iacobuzio-Donahue, Chaitanya Bandlamudi and Eileen M. O’Reill
Erman Akkus is a medical oncology fellow at Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education at the Medical University of Vienna.
More posts featuring Erman Akkus.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023